Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 4/20 | 0.64 |
| ▸ | HTR1D | P28221 | 2/20 | 0.64 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10566668 | 0.94 | HTR1B (0.66) | HTR1BHTR1DCHRNB2CHRNA4L3MBTL1 | |
| SCHEMBL1282727 | 0.80 | DRD4 (0.47) | HTR1BHTR1DKDM4EDRD2DRD4 | |
| SCHEMBL10785918 | 0.79 | KCNA3 (0.43) | HTR1BHTR1DKDM4EALDH1A1DRD2 | |
| SCHEMBL7444282 | 0.79 | DRD4 (0.50) | HTR1BKDM4EDRD2DRD4DRD3 | |
| SCHEMBL7444284 | 0.79 | ADRB2 (0.49) | HTR1BHTR1DKDM4EALDH1A1 | |
| SCHEMBL595753 | 0.78 | HTR1B (1.00) | HTR1BHTR1DCHRNB2CHRNA4L3MBTL1 | |
| SCHEMBL4001304 | 0.78 | MTNR1A (0.53) | L3MBTL1ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL10921722 | 0.77 | HTR1B (0.96) | HTR1BHTR1DCHRNB2CHRNA4L3MBTL1 | |
| SCHEMBL2468934 | 0.77 | HTR1B (0.67) | HTR1BHTR1DCHRNB2CHRNA4L3MBTL1 | |
| Iodide SCHEMBL30481083 | 0.77 | HTR1B (0.96) | HTR1BHTR1DCHRNB2CHRNA4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931670-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | EXELIXIS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8247408-B2 | Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer | EXELIXIS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1931670-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K | Exelixis, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007044698-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| CN-1067071-C | Carboline derivatives | ICOS CORP (US) | 2001-06-13 | — | — | CN | disclosed |
| CN-1218471-A | Carboline derivatives | ICOS CORP (US) | 1999-06-02 | — | — | CN | disclosed |
| EP-0070133-B1 | SECONDARY PHENYLETHANOL AMINES, PROCESSES FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL APPLICATION | BEECHAM GROUP PLC (GB) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | PIK3CA, PIK3CD, PIK3CB | HTR1B 2621/4885HTR1D 1759/4885CHRNB2 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.